These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11). Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002 [TBL] [Abstract][Full Text] [Related]
8. The impact of primary packaging on the quality of parenteral products. Solomun L; Ibric S; Boltic Z; Djuric Z; Stupar B J Pharm Biomed Anal; 2008 Nov; 48(3):744-8. PubMed ID: 18786797 [TBL] [Abstract][Full Text] [Related]
9. Development of a parenteral formulation of trimelamol, a synthetic S-triazine carbinolamine-containing cytotoxic agent. Gibson M; Denham AJ; Taylor PM; Payne NI J Parenter Sci Technol; 1990; 44(6):306-13. PubMed ID: 2277318 [TBL] [Abstract][Full Text] [Related]
10. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes. Stevens PJ; Lee RJ Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245 [TBL] [Abstract][Full Text] [Related]
11. Particulate evaluation of parenteral nutrition solutions by electronic particle counting and scanning electron microscopy. Akers MJ; Schrank GD; Russell S Am J Hosp Pharm; 1981 Sep; 38(9):1304-7. PubMed ID: 6792911 [TBL] [Abstract][Full Text] [Related]
12. In line final filters for removing particles from amphotericin B infusions. Huber RC; Riffkin C Am J Hosp Pharm; 1975 Feb; 32(2):173-6. PubMed ID: 237416 [TBL] [Abstract][Full Text] [Related]
13. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods. Werk T; Volkin DB; Mahler HC Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624 [TBL] [Abstract][Full Text] [Related]
15. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466 [TBL] [Abstract][Full Text] [Related]
16. A new coincidence model for single particle counters, Part I: Theory and experimental verification. Knapp JZ; Abramson LR J Pharm Sci Technol; 1994; 48(3):110-34. PubMed ID: 8069513 [TBL] [Abstract][Full Text] [Related]
18. A new coincidence model for single particle counters, Part II: Advances and applications. Knapp JZ; Lieberman A; Abramson LR PDA J Pharm Sci Technol; 1994; 48(5):255-92. PubMed ID: 8000900 [TBL] [Abstract][Full Text] [Related]
19. Upflow anaerobic sludge blanket reactor--a review. Bal AS; Dhagat NN Indian J Environ Health; 2001 Apr; 43(2):1-82. PubMed ID: 12397675 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress. Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]